Technology Bundle ID: NCI-E-765-2013

Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics

Request More Info
Licensing Contact:
Primary Inventors: 
Bruce Shapiro (NCI)
Angelica Martins (), Kirill Afonin (), Mathias Viard ()
Development Status: 

Pre-clinical (in vivo)

Institute or Center: 

The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present invention discloses novel RNA  and RNA/DNA nanoparticles including  multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. These RNA nanoparticles are useful for various nanotechnological applications. This technology has a higher detection sensitivity and higher silencing efficiencies of targeted genes than conventional siRNAs.  This technology has significant therapeutic potential against multiple disease types, including, cancer and viral infections.  Xxenograft mouse models indicated uptake of the nanoparticles, and six different HIV targets were validated with cell cultures.

  • Treatment for cancer and HIV
  • Potential for higher sensitivity, higher efficiency, low cytotoxicity, multiple functionality, multiple targets, and controlled activation


US National Stage Application 15/022,530
Filed on 2016-03-16


Kirill A. Afonin, et al. "Triggering of RNA Interference with RNA-RNA, RNA-DNA, and DNA- RNA Nanoparticles" 
PMID: 25521794